MK-677 vs Growth Hormone: oral secretagogue vs injectable GH
MK-677 stimulates endogenous GH release (oral, lower ceiling, more insulin resistance per IU-equivalent). Exogenous GH bypasses the pituitary (injectable, no ceiling, dose-titratable, more expensive).
Overview
MK-677 and exogenous growth hormone both elevate IGF-1 and GH, but through fundamentally different mechanisms. MK-677 stimulates your pituitary to produce more GH. Exogenous GH bypasses the pituitary entirely.
MK-677 is oral, affordable, and convenient, but limited by your pituitary's capacity to respond. It produces continuous, non-pulsatile GH elevation with significant insulin resistance relative to the IGF-1 achieved. Its ceiling is roughly equivalent to 2-3 IU/day of exogenous GH.
Exogenous GH is injectable, expensive, and requires careful storage and reconstitution. It has no ceiling (dose determines response), can be precisely titrated, and produces a more pulsatile pattern (peak-and-trough with each injection). At equivalent IGF-1 levels, exogenous GH may cause less insulin resistance than MK-677 due to the peak-and-trough pattern allowing inter-dose recovery.
The choice depends on budget, desired IGF-1 level, metabolic tolerance, and comfort with injections.
Side-by-Side Comparison
| Attribute | MK-677 (Ibutamoren) | Growth Hormone |
|---|---|---|
| Route | Oral (once daily) | Subcutaneous injection (1-2x daily) |
| Mechanism | Stimulates endogenous GH | Bypasses pituitary |
| IGF-1 ceiling | ~2-3 IU GH equivalent | No ceiling (dose-dependent) |
| GH pattern | Continuous, non-pulsatile | Peak-and-trough (pulsatile) |
| Insulin resistance | Higher per IU-equivalent | Lower per IU-equivalent |
| Appetite effect | Strong increase | None |
| Cost (monthly) | $30-60 | $200-600+ (pharma grade) |
| Pituitary effect | Stimulates (preserves function) | Suppresses at high doses |
| Dose precision | Fixed (10-25 mg tablets) | Fully titratable (0.5-15+ IU) |
| Quality control | Research chemical, variable | cGMP pharmaceutical |
Key Differences
Mechanism: MK-677 stimulates endogenous GH release from the pituitary via ghrelin receptor activation. Exogenous GH is recombinant human GH injected directly, bypassing the pituitary entirely.
Dose ceiling: MK-677 is limited by pituitary capacity. At 25 mg/day, most users achieve IGF-1 equivalent to 2-3 IU of GH. Exogenous GH has no ceiling: 2 IU for anti-aging, 4-6 IU for body composition, 8-15+ IU for competitive bodybuilding.
GH pattern: MK-677 produces continuous, sustained GH over 24 hours (no trough). Exogenous GH produces a peak (1-3 hours post-injection) followed by a trough, creating recovery windows for insulin sensitivity.
Insulin resistance: Paradoxically, MK-677 may produce more insulin resistance per unit of IGF-1 achieved than equivalent-dose exogenous GH. The continuous GH stimulation eliminates the insulin sensitivity recovery windows that occur between exogenous GH injections.
Appetite: MK-677 significantly increases appetite via ghrelin receptor activation. Exogenous GH does not affect appetite.
Cost: MK-677 is dramatically cheaper ($30-60/month vs. $200-600+/month for pharmaceutical-grade GH).
Pituitary preservation: MK-677 maintains pituitary function (it stimulates the gland, not replaces it). Long-term exogenous GH at high doses can suppress endogenous GH production via negative feedback.
Quality control: Pharmaceutical GH is manufactured under cGMP with precise dosing. MK-677 is a research chemical with documented product quality concerns.
When to Use Which
Choose MK-677 if:
- Budget is a primary consideration
- You want moderate IGF-1 elevation (equivalent to 2-3 IU GH)
- You prefer oral dosing over injections
- You are in a bulking phase where appetite increase is welcome
- You want to maintain pituitary function
Choose exogenous GH if:
- You need higher IGF-1 levels than MK-677 can achieve
- You are metabolically sensitive and want the ability to titrate dose precisely
- You want better insulin resistance profile per unit of IGF-1
- Appetite stimulation would be counterproductive
- You can afford pharmaceutical-grade product
- You are competing and need consistent, predictable dosing
Clinical Context
From a clinical perspective, exogenous GH has decades of FDA-regulated data for GH deficiency, HIV wasting, and paediatric growth disorders. MK-677 has 2-year RCT data but no FDA approval for any indication. The metabolic comparison is nuanced: while both raise IGF-1 and cause insulin resistance, MK-677's continuous GH pattern and ghrelin-receptor-mediated appetite effects create a distinct metabolic profile that may be more burdensome per unit of IGF-1 achieved.
Bodybuilder Context
In the bodybuilding community, MK-677 is often positioned as the 'poor man's GH,' and this is largely accurate from an efficacy standpoint. It provides moderate GH benefits at a fraction of the cost. However, users who graduate from MK-677 to exogenous GH frequently report that GH feels 'cleaner' with less bloating, water retention, and appetite disruption at equivalent IGF-1 levels. For advanced athletes using GH at 4+ IU/day, MK-677 simply cannot compete. For recreational users wanting modest anti-aging and recovery benefits, MK-677 provides 80% of the benefit at 10% of the cost.
Frequently Asked Questions
Related Pages
Compare your own results
Upload your blood tests to track both markers side by side with personalised trends and AI-powered analysis.